See the published version of this preprint at Diabetology & Metabolic Syndrome.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Qian Li
Nanjing First Hospital
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Asprosin, a novel adipokine which raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM.
Methods
This study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI) ≥ 23.0 kg/m² and haemoglobin A1c (HbA1c) levels of 58 ~ 85 mmol/mol (7.5%~10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n = 19) or placebo (n = 10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. In addition, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and at 24 weeks.
Results
At 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower the levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P < 0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P < 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment.
Conclusions
This study shows that SGLT2 inhibitors can decrease the levels of serum asprosin in patients with newly diagnosed T2DM, which may be involved in SGLT2 inhibitors mechanisms of improving glucose levels and reducing cardiovascular diseases risk factors.
Trial registration
ISRCTN, ISRCTN2013L01573. Registered 29 august 2013. http://www.icmje.org/search/?q=ISRCTN+2013L01573
ISRCTN, ISRCTN2014L00001.Registered 4 January http://www.icmje.org/search/?q=ISRCTN+2014L00001
Keywords
asprosin, SGLT2 inhibitors, type 2 diabetes mellitus, treatment
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Diabetology & Metabolic Syndrome.
Version (no preprint)
Posted 09 Feb, 2021
Editorial decision: Major revision
On 09 Feb, 2021
Review #1 received
Received 08 Feb, 2021
Reviews received
Received 02 Feb, 2021
Reviewer #1 agreed
On 02 Feb, 2021
Editor assigned
On 28 Jan, 2021
Reviewers invited
Invitations sent on 28 Jan, 2021
Submission checks complete
On 28 Jan, 2021
Editor invited
On 28 Jan, 2021
First submitted
On 27 Jan, 2021
This version was not preprinted
No community comments so far
Editor assigned
On 28 Jan, 2021
Reviewers invited
Invitations sent on 28 Jan, 2021
Submission checks complete
On 28 Jan, 2021
Editor invited
On 28 Jan, 2021
Version 1
Posted 16 Dec, 2020
No comments provided
Review #2 received
Received 12 Jan, 2021
Editorial decision: Major revision
On 12 Jan, 2021
Reviewer #2 agreed
On 07 Jan, 2021
Review #1 received
Received 03 Jan, 2021
Reviewer #1 agreed
On 21 Dec, 2020
Reviewers invited
Invitations sent on 07 Dec, 2020
Editor assigned
On 04 Dec, 2020
Submission checks complete
On 04 Dec, 2020
Editor invited
On 04 Dec, 2020
First submitted
On 02 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at Diabetology & Metabolic Syndrome.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Qian Li
Nanjing First Hospital
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Diabetology & Metabolic Syndrome.
Version (no preprint)
Posted 09 Feb, 2021
Editorial decision: Major revision
On 09 Feb, 2021
Review #1 received
Received 08 Feb, 2021
Reviews received
Received 02 Feb, 2021
Reviewer #1 agreed
On 02 Feb, 2021
Editor assigned
On 28 Jan, 2021
Reviewers invited
Invitations sent on 28 Jan, 2021
Submission checks complete
On 28 Jan, 2021
Editor invited
On 28 Jan, 2021
First submitted
On 27 Jan, 2021
This version was not preprinted
No community comments so far
Editor assigned
On 28 Jan, 2021
Reviewers invited
Invitations sent on 28 Jan, 2021
Submission checks complete
On 28 Jan, 2021
Editor invited
On 28 Jan, 2021
Version 1
Posted 16 Dec, 2020
No comments provided
Review #2 received
Received 12 Jan, 2021
Editorial decision: Major revision
On 12 Jan, 2021
Reviewer #2 agreed
On 07 Jan, 2021
Review #1 received
Received 03 Jan, 2021
Reviewer #1 agreed
On 21 Dec, 2020
Reviewers invited
Invitations sent on 07 Dec, 2020
Editor assigned
On 04 Dec, 2020
Submission checks complete
On 04 Dec, 2020
Editor invited
On 04 Dec, 2020
First submitted
On 02 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Diabetology & Metabolic Syndrome.
Background
Asprosin, a novel adipokine which raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) inhibitors for hypoglycemic effect and cardiovascular protection have not been fully clarified. Therefore, we conducted this study to assess change in the levels of serum asprosin after treatment with SGLT2 inhibitors in patients with newly diagnosed T2DM.
Methods
This study was a randomized, double-blind, placebo-controlled trial. A total of 29 participants with newly diagnosed T2DM with body mass index (BMI) ≥ 23.0 kg/m² and haemoglobin A1c (HbA1c) levels of 58 ~ 85 mmol/mol (7.5%~10%) were randomized to SGLT2 inhibitors dapagliflozin 10 mg/d (n = 19) or placebo (n = 10) treatment for 24 weeks. We analyzed asprosin concentrations by an enzyme-linked immunosorbent assay. In addition, body weight, BMI, HbA1c, fasting plasma glucose (FPG), and lipid levels were measured at baseline and at 24 weeks.
Results
At 24 weeks, participants with SGLT2 inhibitors treatment exhibited lower the levels of serum asprosin (22.87 vs 45.06 ng/ml in the placebo group; P < 0.001) after adjusting for baseline values. The levels of body weight, BMI, HbA1c, FPG and triglyceride (TG) were decreased, while high density lipoprotein-cholesterol (HDL-C) was increased after SGLT2 inhibitors dapagliflozin treatment compared with placebo (P < 0.05 for all). Low density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were unchanged in SGLT2 inhibitors group and placebo group. No statistical correlation was found between the levels of serum asprosin and body weight, BMI, HbA1c, FPG, and lipid levels during the SGLT2 inhibitor dapagliflozin treatment.
Conclusions
This study shows that SGLT2 inhibitors can decrease the levels of serum asprosin in patients with newly diagnosed T2DM, which may be involved in SGLT2 inhibitors mechanisms of improving glucose levels and reducing cardiovascular diseases risk factors.
Trial registration
ISRCTN, ISRCTN2013L01573. Registered 29 august 2013. http://www.icmje.org/search/?q=ISRCTN+2013L01573
ISRCTN, ISRCTN2014L00001.Registered 4 January http://www.icmje.org/search/?q=ISRCTN+2014L00001
Figure 1
Loading...